ArticleCommunications biology2023

Development of a 1:1-binding biparatopic anti-TNFR2 antagonist by reducing signaling activity through epitope selection.

Hiroki Akiba et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.